Amy Warriner
Basic profileAmy Warriner is an Endocrinology/Metabolic physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 51 publications with 1,409 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Sponsor: University of Alabama at Birmingham
- Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
Sponsor: University of Alabama at Birmingham
- Bone Mineral Density in HIV+ Patients
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AbbVieProgram year20256 paymentsResearch$23,772
- TakedaProgram year20252 paymentsResearch$530
- Neurocrine BioSciences, Inc.Program year20251 payment$24
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
47.6%GLP-1 receptor agonist21.3%Mounjaro41%Trulicity39%Ozempic20%Part D≥28 patientsInsulin Analog9.6%Tresiba Flextouch U-10031%Lantus Solostar25%Novolog Flexpen22%Toujeo Solostar13%Humalog Kwikpen U-1008%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
24.6%Parathyroid Hormone Analog10.5%Forteo100%Part D≥30 patientsl-Thyroxine10.1%Levothyroxine Sodium87%Synthroid13%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
13%Bisphosphonate5.4%Zoledronic Acid100%Part D≥101 patientsBisphosphonates3.8%Risedronate Sodium100%Part D≥17 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Suzanne Oparil, MD
University of Alabama at Birmingham
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
John Hauth, MD
University of Alabama at Birmingham
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”